CI Global Health Sciences Corporate Class

Series A USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2026-04-30
$129.2 million
NAVPS
As at 2026-05-25
$36.4644
MER (%)
As at 2025-09-30
2.34
Management fee (%) 1.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.7240

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 301
DSC SO* 401
LL SO 1401
F 324
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-04-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-10.27% -1.36% -10.10% -4.14% -1.96% -2.33% -3.79% 1.17% 6.86%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.7240
2021-03-26 0.2492
2020-12-18 0.3973
2020-09-25 0.3778
2020-06-26 0.2765
Payable date Total
2020-03-20 0.6464
2019-12-13 0.4049
2019-09-27 0.4529
2019-06-21 0.4275
2019-03-22 0.6736

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series A USD
 
Portfolio allocations4 As at 2026-04-30
Asset allocation (%)
  • US Equity 84.90
  • International Equity 14.80
  • Cash and Equivalents 0.30
Sector allocation (%)
  • Healthcare 96.47
  • Exchange Traded Fund 3.23
  • Cash and Cash Equivalent 0.30
Geographic allocation(%)
  • United States 84.83
  • United Kingdom 9.19
  • Switzerland 3.40
  • Netherlands 2.26
  • Canada 0.32
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 13.61%
2. AstraZeneca PLC Drugs 8.17%
3. Thermo Fisher Scientific Inc Healthcare Equipment 8.09%
4. Johnson & Johnson Drugs 7.59%
5. IQVIA Holdings Inc Drugs 6.29%
6. DexCom Inc Healthcare Equipment 5.46%
7. UnitedHealth Group Inc Healthcare Services 5.21%
8. Intuitive Surgical Inc Healthcare Equipment 5.19%
9. Danaher Corp Healthcare Equipment 4.93%
10. Stryker Corp Healthcare Equipment 4.73%
11. Merck & Co Inc Drugs 4.50%
12. Boston Scientific Corp Healthcare Equipment 4.15%
13. Vertex Pharmaceuticals Inc Drugs 3.31%
14. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.23%
15. AbbVie Inc Drugs 3.12%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.